Neurim Pharmaceuticals Ltd - Product Pipeline Review - 2015

Date: February 24, 2015
Pages: 35
Price:
US$ 1,500.00 US$ 1,200.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N90B65BCC92EN
Leaflet:

Download PDF Leaflet

Neurim Pharmaceuticals Ltd - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Neurim Pharmaceuticals Ltd - Product Pipeline Review - 2015’, provides an overview of the Neurim Pharmaceuticals Ltd’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Neurim Pharmaceuticals Ltd’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Neurim Pharmaceuticals Ltd including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Neurim Pharmaceuticals Ltd’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Neurim Pharmaceuticals Ltd’s pipeline products
Reasons to buy
  • Evaluate Neurim Pharmaceuticals Ltd’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Neurim Pharmaceuticals Ltd in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Neurim Pharmaceuticals Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Neurim Pharmaceuticals Ltd and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Neurim Pharmaceuticals Ltd
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Neurim Pharmaceuticals Ltd and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Neurim Pharmaceuticals Ltd Snapshot
Neurim Pharmaceuticals Ltd Overview
Key Information
Key Facts
Neurim Pharmaceuticals Ltd - Research and Development Overview
Key Therapeutic Areas
Neurim Pharmaceuticals Ltd - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Neurim Pharmaceuticals Ltd - Pipeline Products Glance
Neurim Pharmaceuticals Ltd - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
Neurim Pharmaceuticals Ltd - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Neurim Pharmaceuticals Ltd - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Neurim Pharmaceuticals Ltd - Drug Profiles
melatonin ER
Product Description
Mechanism of Action
R&D Progress
piromelatine
Product Description
Mechanism of Action
R&D Progress
Neu-120
Product Description
Mechanism of Action
R&D Progress
Neu-107
Product Description
Mechanism of Action
R&D Progress
Neu-164
Product Description
Mechanism of Action
R&D Progress
Neu-240
Product Description
Mechanism of Action
R&D Progress
Neu-AZ1
Product Description
Mechanism of Action
R&D Progress
NeuP-12
Product Description
Mechanism of Action
R&D Progress
Neurim Pharmaceuticals Ltd - Pipeline Analysis
Neurim Pharmaceuticals Ltd - Pipeline Products by Target
Neurim Pharmaceuticals Ltd - Pipeline Products by Route of Administration
Neurim Pharmaceuticals Ltd - Pipeline Products by Molecule Type
Neurim Pharmaceuticals Ltd - Pipeline Products by Mechanism of Action
Neurim Pharmaceuticals Ltd - Recent Pipeline Updates
Neurim Pharmaceuticals Ltd - Dormant Projects
Neurim Pharmaceuticals Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Neurim Pharmaceuticals Ltd, Key Information
Neurim Pharmaceuticals Ltd, Key Facts
Neurim Pharmaceuticals Ltd - Pipeline by Indication, 2015
Neurim Pharmaceuticals Ltd - Pipeline by Stage of Development, 2015
Neurim Pharmaceuticals Ltd - Monotherapy Products in Pipeline, 2015
Neurim Pharmaceuticals Ltd - Phase III, 2015
Neurim Pharmaceuticals Ltd - Phase II, 2015
Neurim Pharmaceuticals Ltd - Phase I, 2015
Neurim Pharmaceuticals Ltd - Preclinical, 2015
Neurim Pharmaceuticals Ltd - Pipeline by Target, 2015
Neurim Pharmaceuticals Ltd - Pipeline by Route of Administration, 2015
Neurim Pharmaceuticals Ltd - Pipeline by Molecule Type, 2015
Neurim Pharmaceuticals Ltd - Pipeline Products by Mechanism of Action, 2015
Neurim Pharmaceuticals Ltd - Recent Pipeline Updates, 2015
Neurim Pharmaceuticals Ltd - Dormant Developmental Projects,2015
Neurim Pharmaceuticals Ltd, Subsidiaries

LIST OF FIGURES

Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Indication, 2015
Neurim Pharmaceuticals Ltd - Pipeline by Stage of Development, 2015
Neurim Pharmaceuticals Ltd - Monotherapy Products in Pipeline, 2015
Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Target, 2015
Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Route of Administration, 2015
Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Molecule Type, 2015
Neurim Pharmaceuticals Ltd - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


Ask Your Question

Neurim Pharmaceuticals Ltd - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: